Humana (NYSE:HUM) Price Target Cut to $265.00

by · The Cerbat Gem

Humana (NYSE:HUM – Get Free Report) had its price objective cut by investment analysts at Royal Bank of Canada from $400.00 to $265.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has an “outperform” rating on the insurance provider’s stock. Royal Bank of Canada’s price objective points to a potential upside of 7.97% from the stock’s previous close.

Several other equities analysts have also recently commented on HUM. Piper Sandler cut Humana from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $392.00 to $274.00 in a research note on Thursday, October 3rd. Jefferies Financial Group downgraded shares of Humana from a “buy” rating to a “hold” rating and reduced their price objective for the company from $519.00 to $253.00 in a research note on Monday. Truist Financial raised their price objective on shares of Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a report on Monday, July 15th. JPMorgan Chase & Co. upped their target price on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a research note on Wednesday, August 21st. Finally, Leerink Partners downgraded Humana from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $400.00 to $250.00 in a research note on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, eighteen have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $324.86.

Read Our Latest Stock Analysis on Humana

Humana Price Performance

HUM opened at $245.43 on Tuesday. Humana has a twelve month low of $213.31 and a twelve month high of $530.54. The firm has a market cap of $29.57 billion, a price-to-earnings ratio of 15.28, a PEG ratio of 2.44 and a beta of 0.50. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The company has a fifty day simple moving average of $331.35 and a 200 day simple moving average of $341.88.

Humana (NYSE:HUM – Get Free Report) last announced its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.89 by $1.07. The business had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The company’s revenue for the quarter was up 10.4% compared to the same quarter last year. During the same period in the previous year, the company earned $8.94 earnings per share. Equities research analysts expect that Humana will post 16.01 EPS for the current fiscal year.

Institutional Investors Weigh In On Humana

A number of hedge funds have recently made changes to their positions in the business. Pzena Investment Management LLC grew its holdings in Humana by 538.7% in the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after buying an additional 1,955,375 shares in the last quarter. Ontario Teachers Pension Plan Board boosted its position in Humana by 11,647.2% during the 1st quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock worth $367,342,000 after acquiring an additional 1,050,459 shares during the period. Marshall Wace LLP grew its stake in shares of Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after purchasing an additional 774,085 shares in the last quarter. Putnam Investments LLC increased its holdings in shares of Humana by 550.3% during the fourth quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock valued at $400,808,000 after purchasing an additional 740,858 shares during the period. Finally, Steadfast Capital Management LP bought a new stake in shares of Humana during the first quarter valued at about $158,813,000. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Read More